Diagnosing neurological disease has always been more art than science. Clinicians rely on subjective observations like watching a patient walk or tracking a finger, tools that haven’t meaningfully changed in 60 years. neuroClues is changing that by turning eye movements into objective, AI powered neurological biomarkers, and it just secured €10 million in Series A funding to scale that work across Europe.
The round was led by Teampact Ventures, White Fund, and the EIC Fund (European Innovation Council), with continued participation from existing investors including InvestBW, Leansquare, and Wallonie Entreprendre. Combined with additional non-dilutive funding, total capital raised by neuroClues now sits at €25 million.
The Diagnosis Problem:
Neurodegenerative diseases affect 1 in 3 people, and the numbers are growing. The global Parkinson’s disease patient population is expected to double to 13 million by 2040.
Despite that scale, 1 in 5 patients is still misdiagnosed. By the time a correct diagnosis arrives, up to 65% of affected neurons have already been lost. The gap exists because clinicians lack practical, quantitative tools at the point of care. Advanced imaging helps, but it’s expensive, not widely accessible, and often misses early stage abnormalities.
Eye Tracking as a Biomarker:
neuroClues built a portable, CE marked Class IIa medical device that addresses this directly. The device captures high speed infrared images of both eyes while a patient performs simple visual tasks. Proprietary AI algorithms then compute objective, reproducible neurological biomarkers from those eye movements, all within a 10 minute exam.
The science backing this isn’t new. Over 80,000 published research papers link eye movement patterns to neurological conditions. What neuroClues has done is translate that body of research into a clinical tool that works within a standard consultation, no specialist lab or long wait required. Today the platform supports objective assessment of neurological anomalies. As clinical data accumulates at scale, it’s designed to support differentiation between conditions like Parkinson’s and atypical parkinsonisms, early Alzheimer’s markers, and concussion related impairments.
From CE Mark to 7 Countries:
neuroClues received CE certification in January 2025. Within months, the company deployed over 30 devices across France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the United Kingdom, placing them in university hospitals, private neurology practices, and research centers.
That commercial momentum is backed by meaningful institutional partnerships. The device is integrated into the Paris Brain Institute’s clinical cohorts, including the Iceberg study on Parkinson’s disease. It’s also been selected for a mega cohort of 25,000 participants aimed at building the first large scale normative database of oculomotor biomarkers. On the commercial side, neuroClues brought on Bart Stulens, former VP Neuromodulation EMEA at Medtronic, as Chief Commercial Officer, and is scaling its European sales team with distributor agreements underway across the EMEA region.
The U.S. Entry Ahead:
The Series A also funds preparation for U.S. market entry. While neuroClues is currently available for clinical use across Europe under its CE mark, regulatory approvals outside the EU are still in progress. The U.S. represents a major expansion opportunity in AI-powered neurological diagnostics, and the company is actively working toward it.
Romain Vidal, Founding Partner at Teampact Ventures, described the investment thesis directly: neuroClues combines scientific depth with commercial readiness, a combination that’s rare in MedTech. That framing holds up when you look at the timeline.
Citizen Co-Investment Open:
Alongside the institutional round, neuroClues opened a limited tranche of up to €1.5 million on LITA, a European impact investment platform. This allows individual investors to participate in the round on the same terms as institutional backers. The window is limited in size and duration.
neuroClues was founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget, a CNRS director at the Paris Brain Institute. The company operates under P3Lab SRL and is based in Louvain-la-Neuve, Belgium, with a presence in Paris.
For founders and operators building in the HealthTech or MedTech space, neuroClues is a useful case study in regulated product commercialization. Getting a Class IIa device CE marked and commercially deployed across seven countries in under 12 months is a meaningful operational achievement worth understanding.
